Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten ...

Closing of the private placement and the debt settlement is subject to customary closing conditions and the Company intends to close as soon as practicable. All of the securities will be subject to a ...